Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

DepoDur®

DepoDur® (morphine sulfate extended-release liposome injection) is an extended-release, injectable formulation of morphine utilizing Pacira's DepoFoam® technology. DepoDur is indicated for epidural administration for the treatment of pain following major surgery. DepoDur is designed to provide effective pain relief for up to 48 hours following one epidural injection and has demonstrated improved patient mobility and freedom from indwelling catheters. DepoDur was approved by the FDA in 2004. For more information, please visit www.depodur.com.

IMPORTANT SAFETY INFORMATION for DepoDur
In clinical trials, the majority of adverse events reported were typical opioid-related side effects, expected in the surgical populations studied. As with all opioids, the most serious side effect of morphine sulfate is respiratory depression, especially in elderly and debilitated patients, and in those with compromised respiratory function. The most common adverse events (greater than 10%) were decreased oxygen saturation, hypotension, urinary retention, vomiting, constipation, nausea, pruritus, pyrexia, anemia, headache, and dizziness.

FULL PRESCRIBING INFORMATION

To report an adverse event, e-mail drugsafety@pacira.com, dial 1-855-397-2467, Option #1, or fax 1-858-408-3588 or 1-973-201-0649.

For medical inquiries related to DepoDur, contact Medical Information at medinfo@pacira.com or 1-855-397-2467, Option #2.